- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Undiscovered Growth Opportunities
Global Pharmaceuticals & Biotech Undiscovered Growth Opportunities
UPDATED Jun 30, 2022
The market has not yet priced in the high-growth prospects for these companies, featuring low PEG ratio (less than 0.5), high future growth outlook and good value on the Snowflake.
21 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| UQ1uniQure | US$17.92 | 19.9% | -31.5% | US$861.6m | US$51.37 | PE2.7x | E22.6% | n/a | ||
| 84CClene | US$3.84 | 0% | -58.7% | US$167.6m | US$21.01 | PE10.1x | E82.7% | n/a | ||
| AVIRAtea Pharmaceuticals | US$7.10 | 2.3% | -66.7% | US$591.1m | US$10.25 | PE12.2x | E45.3% | n/a | ||
| QUREuniQure | US$18.64 | -4.6% | -40.4% | US$869.5m | US$52.95 | PE2.7x | E22.6% | n/a | ||
| UQ1uniQure | US$17.53 | 22.2% | -31.7% | US$861.6m | US$50.25 | PE2.7x | E22.6% | n/a | ||
| CLNNClene | US$2.52 | -9.0% | -77.4% | US$159.4m | US$14.50 | PE9.6x | E82.7% | n/a | ||
| AYURAyurcann Holdings | CA$0.10 | -4.8% | -51.2% | CA$12.1m | n/a | PE30.3x | E138.3% | n/a | ||
| 1061Essex Bio-Technology | HK$3.90 | 0% | -46.6% | HK$2.2b | HK$7.00 | PE6.5x | E21.1% | 2.8% | ||
| 3ZQ0Ayurcann Holdings | CA$0.074 | 1.4% | -42.5% | CA$12.7m | n/a | PE31.8x | E138.3% | n/a | ||
| VB0Viva Biotech Holdings | HK$0.32 | 5.2% | -69.3% | HK$5.2b | n/a | PE15.4x | E36.0% | 0% | ||
| CRSPCRISPR Therapeutics | US$60.77 | -6.7% | -61.2% | US$4.7b | US$115.30 | PE15.1x | E56.9% | n/a | ||
| 1873Viva Biotech Holdings | HK$2.72 | -5.9% | -72.5% | HK$5.2b | n/a | PE15.4x | E36.0% | 0% | ||
| 1CGCRISPR Therapeutics | US$60.53 | 0% | n/a | US$4.9b | US$110.77 | PE15.7x | E56.9% | n/a | ||
| VBIZ.FViva Biotech Holdings | HK$0.35 | -3.8% | -72.9% | HK$5.2b | n/a | PE15.4x | E36.0% | 0% | ||
| MABMabion | zł21.70 | 3.3% | -68.1% | zł350.7m | zł26.00 | PE13.3x | E70.6% | n/a | ||
| AYUR.FAyurcann Holdings | CA$0.081 | -17.3% | n/a | CA$12.1m | n/a | PE30.3x | E138.3% | n/a | ||
| 272Mabion | zł4.68 | 0.5% | -69.2% | zł358.6m | zł5.48 | PE13.6x | E70.6% | n/a | ||
| X0M1XOMA | US$19.00 | 9.2% | -33.1% | US$233.6m | US$58.07 | PE19.4x | E58.1% | n/a | ||
| CRSP NCRISPR Therapeutics | US$1,245.00 | 8.4% | -60.8% | US$4.9b | US$2,278.74 | PE15.7x | E56.9% | n/a | ||
| XOMAXOMA | US$22.28 | 12.3% | -33.5% | US$254.5m | US$62.50 | PE21.1x | E58.1% | n/a | ||
| C2RS34CRISPR Therapeutics | US$39.51 | 0% | n/a | US$4.7b | US$74.97 | PE15.1x | E56.9% | n/a |
Page 1 of 1